A randomized controlled trial on therapeutic effects of sub-Tenon's capsule injection of triamcinolone acetonide in prevention of occurrence and inhibition of progression of diabetic macular edema caused by panretinal photocoagulation

A randomized controlled trial on therapeutic effects of sub-Tenon's capsule injection of triamcinolone acetonide in prevention of occurrence and inhibition of progression of diabetic macular edema caused by panretinal photocoagulation - A randomized controlled trial on therapeutic effects of sub-Tenon's capsule injection of triamcinolone acetonide in prevention of occurrence and inhibition of progression of diabetic macular edema caused by panretinal photocoagulation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000455

Enrollment

Registered

2006-07-27

Start date

2006-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy

Interventions

A single sub-Tenon&#39

s injection of triamcinolone acetonide (20mg) and panretinal photocoagulation Panretinal photocoagulation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy, whose retinopathy is bilateral and symmetrical, and panretinal ptotocoagulation is required for.

Exclusion criteria

Exclusion criteria: (1)Intraocular pressure is more than 21 mmHg (2)Massive cataract (3)Ocular pathology other than diabetic retinopathy (e.g., glaucoma, age-related macular degeneration) (4)Tractional retinal detachment or massive proliferation (5)Vitreous hemorrhage (6)Unilateral or asymmetrical diabetic retinopathy (7)Neovascular glaucoma (8)Previous vitreoretinal surgery (9)Previous panretinal photocoagulation (10)Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Best-corrected visual acuity (logarithm of the minimum angle of resolution) at 6 months after treatment	—

Secondary

Measure	Time frame
Best-corrected visual acuity (logMAR) at 1,3 months after treatment Foveal thickness at 1week, 1,3,6 months after treatment Intraocular pressure at 1,3,6 months after treatment	—

Countries

Japan

Contacts

Public ContactNoriyuki Unoki

Kyoto University Graduate School of Medicine Department of Ophthalmology

noriharu@kuhp.kyoto-u.ac.jp075-751-3250

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

A randomized controlled trial on therapeutic effects of sub-Tenon&#39;s capsule injection of triamcinolone acetonide in prevention of occurrence and inhibition of progression of diabetic macular edema caused by panretinal photocoagulation